Revenue: As of FY2025 Q3, the actual value is USD 9.351 M.EPS: As of FY2025 Q3, the actual value is USD 0.7.EBIT: As of FY2025 Q3, the actual value is USD 1.105 M.<h3>Segment Revenue</h3><ul><li>Income from Purchased Receivables under the EIR Method: $6,962 thousand for the three months ended September 30, 2025, compared to $5,423 thousand for the same period in 2024. For the nine months ended September 30, 2025, income was $19,039 thousand, compared to $9,985 thousand in 2024.</li><li>Income from Purchased Receivables under the Cost Recovery Method: $1,857 thousand for the three months ended September 30, 2025, compared to $1,040 thousand for the same period in 2024. For the nine months ended September 30, 2025, income was $9,125 thousand, compared to $1,910 thousand in 2024.</li><li>Revenue from Contracts with Customers: $225 thousand for the three months ended September 30, 2025, compared to $25 thousand for the same period in 2024. For the nine months ended September 30, 2025, revenue was $9,250 thousand, compared to $6,050 thousand in 2024.</li><li>Revenue Recognized under Units-of-Revenue Method: $307 thousand for the three months ended September 30, 2025, compared to $709 thousand for the same period in 2024. For the nine months ended September 30, 2025, revenue was $978 thousand, compared to $1,828 thousand in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income: $14,051 thousand for the three months ended September 30, 2025, compared to a net loss of $17,243 thousand for the same period in 2024. For the nine months ended September 30, 2025, net income was $25,609 thousand, compared to a net loss of $9,853 thousand in 2024.</li><li>General and Administrative Expenses: $9,734 thousand for the three months ended September 30, 2025, compared to $8,020 thousand for the same period in 2024. For the nine months ended September 30, 2025, expenses were $25,682 thousand, compared to $27,485 thousand in 2024.</li><li>Research and Development Expenses: $69 thousand for the three months ended September 30, 2025, compared to $817 thousand for the same period in 2024. For the nine months ended September 30, 2025, expenses were $1,431 thousand, compared to $2,011 thousand in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by Operating Activities: $8,372 thousand for the nine months ended September 30, 2025, compared to net cash used in operating activities of $10,845 thousand for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $31,539 thousand for the nine months ended September 30, 2025, compared to $8,172 thousand for the same period in 2024.</li><li>Net Cash Used in Financing Activities: $15,774 thousand for the nine months ended September 30, 2025, compared to $10,061 thousand for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company expects income related to VABYSMO to increase in future periods based on projected sales estimates. Additionally, income from OJEMDA is expected to increase based on projections reported by DayOne.</li><li>Non-Core Business: The company plans to acquire LAVA and Mural through tender offers, with the acquisitions expected to close soon. These acquisitions are part of the company’s strategy to expand its portfolio of economic rights to future potential milestone and royalty payments.</li></ul><h3>Priority</h3><ul><li>The company emphasizes strategies with concrete projections, such as the expected increase in income from VABYSMO and OJEMDA, over generic statements.</li></ul>

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B | 10-Q: FY2025 Q3 Revenue: USD 9.351 M